Corvus Pharmaceuticals (NASDAQ: CRVS) — Stock Profile

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing product candidates that precisely target proteins critical to immune cell maturation and function, with its operations concentrated in the United States. The company's pipeline is built around small molecules and antibody therapies designed to modulate immune pathways, with programs spanning oncology and inflammatory disease indications.

Its lead candidate, soquelitinib, is a selective covalent inhibitor of interleukin 2 inducible T cell kinase currently in a multi-center Phase 1b/2 trial across peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, solid tumors, and asthma. The pipeline also includes ciforadenant, an oral small molecule antagonist of the A2A receptor in Phase 2 development for first-line renal cell cancer, and mupadolimab, a humanized monoclonal antibody in Phase 1 development for non-small cell lung cancer. The company holds license agreements with Monash University, Vernalis (R&D) Limited, and Scripps supporting the research, development, and commercialization of these and related compounds. Corvus Pharmaceuticals was incorporated in 2014 and is headquartered in South San Francisco, California.